No additional next-generation sequencing or broad genomic profiling was conducted on the tumor; this is a limitation of our report, as such analysis might have identified actionable mutations (for example, PIK3CA or ESR1 mutations) to further guide therapy. This evidence concerns the gene ESR1 and neoplasm.